Clinical Factors to Decide Between Sacral Neuromodulation and Onabotulinum Toxin—When Is One Clearly Better?

Purpose of ReviewThis article provides a review of the current literature on the applicability of each treatment for OAB, as well as unique clinical scenarios. In addition, the authors provide their own practical insight on how to approach third-line therapies for OAB.Recent FindingsThe treatment of overactive bladder (OAB) is increasingly common amongst specialists. OnabotulinumtoxinA and sacral neuromodulation are both highly effective third-line therapies for OAB, but work via very different mechanisms. The differences between the two are associated with potential benefits and complications unique for each.SummaryThe OAB clinician must account for several clinical and personal factors in counseling patients on options.